New Chief Medical Officer

Oxurion NV a biopharmaceutical company engaged in the development of next-generation therapies to treat diabetic eye disease, with a focus on diabetic macular edema has announced the appointment of Grace Chang, M.D., Ph.D. as the company’s Chief Medical Officer. Dr. Chang will be responsible for leading the company’s clinical programmes for THR-687 and THR-149 as Oxurion looks to build a world-leading diabetic macular edema (DME) franchise that could provide much improved therapeutic solutions for all DME patients, said a company spokeswoman. Dr. Chang joins Oxurion from Notal Vision Inc, where she held the position of CMO and was responsible for the scientific and clinical strategy, clinical development and medical affairs programs. She is currently an Adjunct Clinical Associate Professor in the Department of Ophthalmology, Vitreoretinal Service at the University of Southern California in Los Angeles, CA. Prior to this, Dr. Chang held several high-level clinical and strategic roles at Alcon Laboratories following a faculty appointment at the University of Washington. Dr. Chang completed her ophthalmology residency and vitreoretinal fellowship at Harvard Medical School, Massachusetts Eye and Ear Infirmary in Boston, MA and earned her M.D. from Stanford University, Stanford, CA. www.oxurion.com